Early Cancer Detection Platform

About Astrin Biosciences

Astrin Biosciences is pioneering a novel diagnostic platform designed to detect cancer in its earliest stages by monitoring real-time biological activity. The company's mission is to shift cancer diagnosis from reactive to proactive, enabling earlier intervention and better survival rates. While still in the development phase, their technology holds significant promise for improving screening paradigms across multiple cancer types. Astrin is positioned as a private, pre-revenue company focused on advancing its platform through research and development.

About Oncodea

Oncodea is an early-stage biotech company operating in the cancer diagnostics sector, leveraging artificial intelligence and machine learning to create a scalable early detection platform. The company emphasizes affordability and accessibility, aiming to shift cancer screening from a reactive to a proactive, routine health measure. While the website suggests a foundation built on 20 years of industry experience, specific technological details, clinical validation status, and leadership are not publicly disclosed. The company appears to be in a pre-revenue, development-focused phase, targeting a significant but highly competitive market opportunity in liquid biopsy and multi-cancer early detection.

Therapeutic Areas

Other Multiple Solid Tumors Drugs